This is called, aptly, obstructive hypertrophic cardiomyopathy. This kind of obstruction is behind many of the more ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

Edgewise Therapeutics has announced positive top-line findings from two clinical trials where its EDG-7500 showed benefit as ...

Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...

Type 2 diabetes impacted left ventricular and atrial function in patients with hypertrophic cardiomyopathy, emphasizing the need for diabetes surveillance.

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of ...

Edgewise's lead drug, Sevasemten, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular ...

of a mid-stage study in patients with obstructive hypertrophic cardiomyopathy (HCM). Per the data readout from the phase I study in healthy adults, no meaningful changes in left ventricle ejection ...

Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at ...

Take hypertrophic cardiomyopathy, or HCM, a primarily genetic condition that results in a thickening of the walls of the heart—specifically its left ventricle, which is the chamber that pumps ...